ANP Technologies®, Inc. Receives $19.7M from NIH/NIBIB/Rapid Acceleration of Diagnostics (RADx) Program for its NIDS® COVID-19 Antigen Rapid Test Kit
Newark, DE (Apr. 16, 2021) – ANP Technologies Inc. (ANP), announced that it has received a highly competitive Phase 2 award totaling $19.7M from NIH/NIBIB/Rapid Acceleration of Diagnostics (RADx) Tech Program for its NIDS® COVID-19 Antigen Rapid Test Kit. This award is based upon ANP’s successful completion of Phase 0 and Phase 1 efforts in less than three months. The rapid antigen test developed by ANP is a nano-intelligent technology enhanced lateral flow immunoassay test that detects SARS-CoV-2 antigens in nasal samples. The test delivers results in 15 minutes at the point of care and is being validated for potential at-home use. Read more at https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-phase2-awards.
“The NIH/RADx award is a further validation of our NIDS® rapid test technology, which has been fully fielded by the Department of Defense for the detection of various biological agents.” Said Dr. Ray Yin, President and CTO of ANP. “Our plug-and-play assay platform allows us to rapidly develop various rapid tests, including multiplexed lateral flow tests, for the detection of SARS-Cov-2 virus, its variants and emerging biothreats.”
About ANP Technologies, Inc.
ANP Technologies, Inc. is a clinical stage biopharmaceutical company and a world leader in developing innovative nano-therapeutics and nano-diagnostic tests. ANP has been a premier provider to supply its rapid multiplexed lateral flow tests for the detection of various biological agents to the Department of Defense in the past 15 years, as well as successfully licensed various pre-clinical and clinical stage nanotherapeutics to companies such as Celgene/BMS and Fulgent Pharma. Visit https://www.anptinc.com for more information.
Greg Witham, MS